Coherus Oncology

CHRSNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$196.216 M

$1.27 +0.40%

Close of 7 Aug 2026

Revenue

—

Not reported

Earnings

$168.0M

#1079 by earnings

Shares outstanding

154,500,966

Latest filing cover page

P/E ratio

1.2

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#96AlectorALEC$197.6M
#97Voyager TherapeuticsVYGR$197.6M
#98Coherus OncologyCHRS$196.2M
#99Precision BiosciencesDTIL$193.3M
#100Outlook TherapeuticsOTLK$190.7M

Where these numbers come from

Share counts and financials for Coherus Oncology are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.